|
KR0149275B1
|
|
Medicaments for the treatment of cerebral apoplexy
|
|
CN1222853A
|
|
Use of phosphonic acid esters for treatment of functional disorders of brain and depression
|
|
PL333464A1
|
|
Application of phosphonic esters in treatment and prophylactics of cerebral functional disorders and depressions
|
|
DE19543476A1
|
|
Treatment of skull-brain trauma with aminomethyl-chroman compounds
|
|
EP0659434A1
|
|
Use of phosphoric and phosphonic acid esters for the treatment of cerebral insufficiency disorders and depressions
|
|
US5438144A
|
|
Use of 1,4-dihydropyridines in diabetes
|
|
EP0547334A1
|
|
Combination of calcium antagonists with cholinesterase inhibitors for the treatment of senile demention
|
|
US5200410A
|
|
Medicaments for the treatment of cerebral apoplexy
|
|
DE4138756A1
|
|
COMBINATION WITH NEUROPROTECTIVE EFFECT
|
|
DE4125116A1
|
|
USE OF 1,4-DIHYDROPYRIDINE IN DIABETES
|
|
DE4039631A1
|
|
Neuro-protective combination for treating cerebral ischaemia - contains a 5-HT1A receptor agonist and 5-HT2 receptor antagonist
|
|
US5187276A
|
|
2-pyrimidinyl-1-piperazine derivatives
|
|
DE3831888A1
|
|
MEDICINES FOR TREATING APOPLEXIA CEREBRI
|
|
DE3806277A1
|
|
USE OF 1,4-DIHYDROPYRIDINE DERIVATIVES
|
|
DE3736974A1
|
|
USE OF 2-PYRIMIDINYL-1-PIPERAZINE DERIVATIVES
|
|
DE3727879A1
|
|
USE OF 2-PYRIMIDINYL-1-PIPERAZINE DERIVATIVES
|
|
DE3718398A1
|
|
NEW COMBINATION DEVICES WITH ANTI-DEPRESSIVE EFFECT
|
|
DE3633484A1
|
|
Lyophilised acemetacin
|
|
DE3632359A1
|
|
PREPARATIONS FOR MEDICINAL PRODUCTS
|
|
US4731384A
|
|
Etofenamate formulation
|
